• Healius releases trading update
  • Incannex reports positive Phase 2 results

Healthcare services provider Healius (ASX:HLS) has released its latest trading update today, which has closely tracked the guidance provided during its Investor Day in May.

The company says its Q3 Imaging business is slightly ahead of the May guidance, while its Pathology business is ahead of Medicare data.

For the year to date to May 31, Healius’ EBIT was in the order of $473 million, a 100% increase on the unaudited underlying EBIT of $234 million for the same period in FY 2021.

Healius says it wants to continue to advance its portfolio simplification as a diagnostics operator, and has completed the sale of its Adora Fertility business this week.

Following that spinoff, the company will now focus on growing its core pathology and imaging businesses.

Healius believes it is well positioned as an incumbent operator with operating leverage, underpinned by its market-leading digital program.

 

Healius share price today:

 

Incannex announces positive Phase 2 results

Incannex (ASX:IHL) has just announced positive results from its Phase 2 clinical trial, investigating the effect of IHL-42X for the treatment of obstructive sleep apnoea (OSA).

The study concluded that IHL-42X reduces the apnoea hypopnoea index (AHI), improves patient’s sleep quality, and is well tolerated.

The clinical trial, conducted at the University of Western Australia, assessed three doses of IHL-42X at reducing the AHI in patients who suffered from OSA.

Trial participants received each of the three doses of IHL-42X and placebo across four seven-day treatment periods, separated by one-week washout periods.

At the end of each treatment period, they attended the clinic for an overnight sleep study where AHI was determined, along with other measures of sleep quality, quality of life and drug safety.

The reduction in AHI observed during the treatment periods means that when treated with Incannex’s IHL-42X, the patient’s breathing was interrupted less frequently during sleep.

This supports Incannex’s hypothesis that IHL-42X is an effective treatment for OSA.

 

Incannex share price today:

 

At Stockhead we tell it like it is. While Incannex Healthcare is a Stockhead advertiser, it did not sponsor this article.

Read MoreBiotech

Featured Companies

You might be interested in